Integrating AQUILA Findings into Care for High-Risk Smoldering Multiple Myeloma

In the closing segment, faculty synthesize the key insights from the AQUILA trial and reflect on how these findings may inform the evolving management of high-risk smoldering multiple myeloma. The discussion revisits the balance between delaying disease progression and minimizing treatment burden in an asymptomatic population, emphasizing the importance of careful patient selection and individualized decision-making.

Panelists share perspectives on how AQUILA data may influence future clinical conversations around risk stratification, timing of intervention, and long-term disease control. Attention is given to areas where additional data and longer follow-up may further clarify optimal approaches to early treatment.

This concluding segment reinforces the program’s central themes and encourages thoughtful consideration of how emerging evidence can be responsibly integrated into clinical practice, while maintaining a patient-centered and evidence-based approach.